%0 Journal Article
%T An overview of the research progress of BRCA gene mutations in breast cancer.
%A Wan A
%A Zhang G
%A Ma D
%A Zhang Y
%A Qi X
%J Biochim Biophys Acta Rev Cancer
%V 1878
%N 4
%D 2023 07 10
%M 37172654
%F 11.414
%R 10.1016/j.bbcan.2023.188907
%X The breast cancer susceptibility gene (BRCA) is an important tumor suppressor gene, including BRCA1 and BRCA2, a biomarker that assesses the risk of breast cancer and influences a patient's individualized treatment options. BRCA1/2 mutation (BRCAm) increases the risk of breast cancer. However, breast-conserving surgery is still an option for BRCAm, and prophylactic mastectomy and nipple-sparing mastectomy may also reduce the risk of breast cancer. BRCAm is sensitive to Poly (ADP-ribose) polymerase inhibitor (PARPi) therapy due to specific types of DNA repair defects, and its combination with other DNA damage pathway inhibitors and endocrine therapy and immunotherapy are also used for the treatment of BRCAm breast cancer. The current treatment and research progress of BRCA1/2 mutant breast cancer in this review provides a basis for the individualized treatment of patients with this type of breast cancer.